Intrexon T1D Partners Overview
- Founded
-
2016
- Status
-
Private
- Latest Deal Type
-
Joint Venture
- Financing Rounds
-
1
Intrexon T1D Partners General Information
Description
Developer of a therapy for the treatment of Type 1 diabetes. The company is focused on development of an antigen-specific immunotherapy both for early-stage patients before they become insulin dependent, and in certain advanced-stage patients for the potential prevention of the requirement for external administration of insulin.
Contact Information
Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 20374 Seneca Meadows Parkway
- Germantown, MD 20876
- United States
Intrexon T1D Partners Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Intrexon T1D Partners Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|